Afficher la notice abrégée

hal.structure.identifierModélisation Mathématique pour l'Oncologie [MONC]
hal.structure.identifierInstitut de Mathématiques de Bordeaux [IMB]
dc.contributor.authorBENZEKRY, Sébastien
dc.date.accessioned2024-04-04T03:02:34Z
dc.date.available2024-04-04T03:02:34Z
dc.date.conference2018-07-09
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/192999
dc.description.abstractEnConcomitant administration of bevacizumab and pemetrexed-cisplatin is a common treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). Vascular normalization following bevacizumab administration may transiently enhance drug delivery, suggesting improved efficacy with sequential administration. To investigate optimal scheduling, we conducted a study in NSCLC-bearing mice that combined mathematical modeling with experimental investigations. First, experiments demonstrated improved efficacy when using sequential vs. concomitant scheduling of bevacizumab and chemotherapy. Combining this data with a mathematical model of tumor growth under therapy accounting for the normalization effect, we predicted an optimal delay of 2.8 days between bevacizumab and chemotherapy. This prediction was confirmed experimentally, with reduced tumor growth of 38% as compared to concomitant scheduling, and prolonged survival (74 vs. 70 days). Alternate sequencing of 8 days failed in achieving a similar increase in efficacy, thus emphasizing the utility of modeling support to identify optimal scheduling. The model could also be a useful tool in the clinic to personally tailor regimen sequences.
dc.language.isoen
dc.subject.enPersonalized oncology
dc.subject.enExperimental therapeutics
dc.subject.enAntiangiogenic drugs
dc.subject.enNonlinear mixed-effects modeling
dc.subject.enCombinations
dc.title.enOptimization of sequential administration of bevacizumab plus cytotoxics in non-small cell lung cancer by combining in vivo experiments and mathematical modeling
dc.typeCommunication dans un congrès
dc.subject.halSciences du Vivant [q-bio]/Cancer
dc.subject.halInformatique [cs]/Modélisation et simulation
dc.subject.halPhysique [physics]/Physique [physics]/Analyse de données, Statistiques et Probabilités [physics.data-an]
dc.subject.halSciences du Vivant [q-bio]/Sciences pharmaceutiques/Pharmacologie
dc.subject.halStatistiques [stat]/Applications [stat.AP]
bordeaux.hal.laboratoriesInstitut de Mathématiques de Bordeaux (IMB) - UMR 5251*
bordeaux.institutionUniversité de Bordeaux
bordeaux.institutionBordeaux INP
bordeaux.institutionCNRS
bordeaux.conference.titleMathematical perspectives in the biology and therapeutics of cancer
bordeaux.countryFR
bordeaux.conference.cityMarseille
bordeaux.peerReviewednon
hal.identifierhal-01969142
hal.version1
hal.invitedoui
hal.proceedingsnon
hal.conference.end2018-07-13
hal.popularnon
hal.audienceInternationale
hal.origin.linkhttps://hal.archives-ouvertes.fr//hal-01969142v1
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.au=BENZEKRY,%20S%C3%A9bastien&rft.genre=unknown


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée